Bing Yao, ArriVent Biopharma CEO
With one of biotech's largest private rounds in a year, ArriVent enters PhIII
Bing Yao’s ArriVent Biopharma has amassed a $155 million oversubscribed Series B, crowning it as one of biotech’s largest private rounds in a year-long difficult …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.